MEDINET Co., Ltd.

Tokyo Stock Exchange 2370.T

MEDINET Co., Ltd. Capital Expenditure for the year ending September 30, 2024: USD -413.37 K

MEDINET Co., Ltd. Capital Expenditure is USD -413.37 K for the year ending September 30, 2024, a 27.14% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • MEDINET Co., Ltd. Capital Expenditure for the year ending September 30, 2023 was USD -567.33 K, a -102.65% change year over year.
  • MEDINET Co., Ltd. Capital Expenditure for the year ending September 30, 2022 was USD -279.95 K, a 8.81% change year over year.
  • MEDINET Co., Ltd. Capital Expenditure for the year ending September 30, 2021 was USD -306.99 K, a -61.17% change year over year.
  • MEDINET Co., Ltd. Capital Expenditure for the year ending September 30, 2020 was USD -190.48 K, a 80.82% change year over year.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
Loading...
SV Wall Street
Tokyo Stock Exchange: 2370.T

MEDINET Co., Ltd.

CEO Kanenao Kubushiro
IPO Date Oct. 8, 2003
Location Japan
Headquarters TRC Center Building
Employees 92
Sector Healthcare
Industries
Description

MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. Its solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy. The company also manufactures regenerative medical/investigational and specified cell products. In addition, its value chain solutions include personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management system, quality control and assurance, and technology transfer and process development solutions. Further, the company supports medical institutions, research institutions, and biopharmaceutical companies to conduct immuno-cell therapy. MEDINET Co., Ltd. was incorporated in 1995 and is headquartered in Tokyo, Japan.

Similar companies

2134.T

Kitahama Capital Partners Co.,Ltd.

USD 0.12

-0.59%

2160.T

GNI Group Ltd.

USD 22.49

-0.83%

4564.T

OncoTherapy Science, Inc.

USD 0.17

0.04%

4591.T

Ribomic Inc.

USD 0.55

-1.73%

StockViz Staff

February 8, 2025

Any question? Send us an email